Ieq Capital LLC Has $3.73 Million Stock Position in Doximity, Inc. $DOCS

Key Points

• Ieq Capital LLC increased its holdings in Doximity, Inc. by 16.9% during the first quarter, bringing its total shares to 64,190, with a current value of approximately $3.7 million.
• Analysts have recently raised their price targets for Doximity, with KeyCorp setting a new target at $70.00, reflecting positive outlooks from multiple firms.
• Insider selling was noted, with Director Regina M. Benjamin selling 5,000 shares for a total of $315,000, indicating a 23.13% decrease in her ownership of the stock.

Ieq Capital LLC raised its position in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 16.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,190 shares of the company's stock after purchasing an additional 9,297 shares during the period. Ieq Capital LLC's holdings in Doximity were worth $3,725,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Doximity by 8.8% during the first quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company's stock valued at $707,646,000 after purchasing an additional 990,923 shares in the last quarter. Invesco Ltd. grew its stake in shares of Doximity by 54.8% during the first quarter. Invesco Ltd. now owns 1,969,326 shares of the company's stock worth $114,280,000 after buying an additional 696,923 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Doximity by 9.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,730,282 shares of the company's stock worth $100,408,000 after buying an additional 150,574 shares during the last quarter. Northern Trust Corp grew its stake in shares of Doximity by 9.4% during the fourth quarter. Northern Trust Corp now owns 1,459,185 shares of the company's stock worth $77,906,000 after buying an additional 125,332 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Doximity by 8.2% during the first quarter. Bank of New York Mellon Corp now owns 1,137,912 shares of the company's stock worth $66,033,000 after buying an additional 86,135 shares during the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Doximity

In related news, Director Timothy S. Cabral sold 10,000 shares of the business's stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director owned 6,360 shares in the company, valued at $381,600. The trade was a 61.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Regina M. Benjamin sold 10,000 shares of the company's stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the transaction, the director owned 16,618 shares in the company, valued at $997,080. This represents a 37.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,000 shares of company stock worth $1,929,380 over the last quarter. Company insiders own 31.30% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on DOCS shares. JPMorgan Chase & Co. decreased their target price on shares of Doximity from $63.00 to $60.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 27th. KeyCorp boosted their target price on shares of Doximity from $65.00 to $70.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Evercore ISI raised shares of Doximity from an "in-line" rating to an "outperform" rating and boosted their target price for the stock from $50.00 to $70.00 in a research note on Wednesday, July 9th. Bank of America boosted their target price on shares of Doximity from $55.00 to $62.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 25th. Finally, William Blair reaffirmed an "outperform" rating on shares of Doximity in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $66.21.

Doximity Trading Up 1.8%

DOCS stock traded up $1.25 during midday trading on Thursday, hitting $68.55. The stock had a trading volume of 693,138 shares, compared to its average volume of 2,264,390. The firm has a market cap of $12.84 billion, a P/E ratio of 68.55, a price-to-earnings-growth ratio of 4.10 and a beta of 1.37. Doximity, Inc. has a 1-year low of $35.32 and a 1-year high of $85.21. The business has a fifty day moving average price of $62.50 and a two-hundred day moving average price of $60.11.

Doximity (NASDAQ:DOCS - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. The company's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period last year, the business earned $0.28 EPS. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, equities analysts anticipate that Doximity, Inc. will post 0.99 EPS for the current year.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.